Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Ann Clin Psychiatry ; 25(1): 41-9, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-23376869

RESUMO

BACKGROUND: Suicide among college students is a significant public health concern. Although suicidality is linked to depression, not all depressed college students experience suicidal ideation (SI). The primary aim of this study was to determine potential factors that may distinguish college students with depressive symptoms with and without SI. METHODS: A total of 287 undergraduate college students with substantial depressive symptoms (Beck Depression Inventory [BDI] total score >13) with and without SI were compared across psychiatric and functional outcome variables. Independent sample t tests were conducted for each outcome variable using the suicide item of the BDI as a dichotomous (ie, zero vs nonzero score) grouping variable. RESULTS: Relative to students with substantial depressive symptoms without SI, those with SI were more symptomatic overall, having significantly higher levels of depressive symptoms, hopelessness, and anxiety. However, contrary to our expectations, nonsuicidal and suicidal students did not differ on measures of everyday functioning (ie, cognitive and physical functioning and grade point average). CONCLUSIONS: Our findings suggest that SI among college students is associated with increased subjective distress but may not adversely impact physical or cognitive functioning or academic performance.


Assuntos
Ansiedade/complicações , Depressão , Estresse Psicológico/complicações , Ideação Suicida , Adaptação Psicológica , Adolescente , Estudos Transversais , Demografia , Depressão/diagnóstico , Depressão/epidemiologia , Depressão/etiologia , Depressão/psicologia , Avaliação Educacional , Função Executiva , Feminino , Humanos , Masculino , Atividade Motora , Escalas de Graduação Psiquiátrica , Psicologia Comparada/métodos , Psicologia Comparada/estatística & dados numéricos , Medição de Risco/métodos , Fatores de Risco , Autoavaliação (Psicologia) , Fatores Socioeconômicos , Adulto Jovem
2.
J Nerv Ment Dis ; 201(11): 953-8, 2013 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-24177482

RESUMO

Depression is a prevalent psychiatric disorder associated with significant personal and societal burden. There is accumulating evidence for the presence of a subtype of depression characterized by the presence of irritability that is associated with increased morbidity, risk for suicidal ideation, and functional impairments in adults. Little is known about the features of depressive symptoms with and without irritability among young adults in college. The primary aim of this study was to characterize the presentation of college students with depressive symptoms and irritability. Two-hundred eighty-seven undergraduate college students with depressive symptoms with and without irritability were compared across several psychiatric and functional outcome variables. Independent samples t-tests or logistic regressions were conducted for each outcome variable using the irritability item of the Beck Depression Inventory as a dichotomous grouping variable. Analyses were conducted separately for the men and the women. Both male and female students with depressive symptoms and severe irritability reported a greater severity of depressive symptoms compared with their peers with no or mild irritability. In the women, the presence of irritability was associated with greater symptoms of anxiety, whereas in the men, it was associated with increased likelihood of engaging in risky behaviors, including compulsive use of alcohol, illicit drugs, and prescription drugs. The male and female college students with depressive symptoms with and without irritability did not differ on severity of suicidal ideation, hopelessness, or cognitive functioning. The findings from this study suggest that depressive symptoms and irritability may characterize a subtype of college students who have a greater symptom burden and with the potential need for more aggressive and prompt treatment.


Assuntos
Depressão/diagnóstico , Depressão/psicologia , Humor Irritável , Estudantes/psicologia , Universidades , Adolescente , Estudos Transversais , Depressão/epidemiologia , Feminino , Humanos , Masculino , Autorrelato , Adulto Jovem
3.
J Clin Psychiatry ; 75(8): 855-63, 2014 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-24813065

RESUMO

OBJECTIVE: Specific genetic or biological markers may predict inadequate response to therapy for major depressive disorder (MDD). The objective of the current post hoc analysis was to evaluate the effect of specific biological and genetic markers on the antidepressant efficacy of adjunctive L-methylfolate 15 mg versus placebo from a trial of inadequate responders to selective serotonin reuptake inhibitors (SSRIs). METHOD: The double-blind, randomized, placebo-controlled trial used the sequential parallel comparison design. Outpatients with SSRI-resistant MDD (DSM-IV criteria) received L-methylfolate 15 mg/d for 60 days, placebo for 30 days followed by L-methylfolate 15 mg/d for 30 days, or placebo for 60 days. The effects of baseline levels of select biological and genetic markers individually and combined on treatment response to L-methylfolate versus placebo were evaluated; the primary response measure was the 28-Item Hamilton Depression Rating Scale (HDRS-28). The first patient was enrolled July 14, 2009, and the last patient completed April 28, 2011. RESULTS: Seventy-five patients were enrolled. Patients with specific biological (body mass index ≥ 30 kg/m², elevated plasma levels of high-sensitivity C-reactive protein or 4-hydroxy-2-nonenal, low S-adenosylmethionine/S-adenosylhomocysteine ratio) and genetic markers at baseline had significantly (P ≤ .05) greater pooled mean change from baseline on the HDRS-28 with L-methylfolate versus placebo. Pooled mean change from baseline on the Clinical Global Impressions-Severity of Illness scale was significantly (P < .05) greater with L-methylfolate versus placebo for most genetic markers. Most combinations of baseline biological and genetic markers predicted significantly (P ≤ .05) greater reductions in pooled mean change from baseline in HDRS-28 scores with L-methylfolate versus placebo. CONCLUSIONS: Biomarkers associated with inflammation or metabolism and genomic markers associated with L-methylfolate synthesis and metabolism may identify patients with SSRI-resistant depression who are responsive to adjunctive therapy with L-methylfolate 15 mg. Confirmatory studies are needed. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00955955.


Assuntos
Aldeídos/sangue , Proteína C-Reativa , Transtorno Depressivo Resistente a Tratamento/tratamento farmacológico , S-Adenosil-Homocisteína/sangue , S-Adenosilmetionina/sangue , Inibidores Seletivos de Recaptação de Serotonina/uso terapêutico , Tetra-Hidrofolatos/uso terapêutico , Adolescente , Adulto , Idoso , Biomarcadores/sangue , Transtorno Depressivo Resistente a Tratamento/sangue , Transtorno Depressivo Resistente a Tratamento/genética , Quimioterapia Combinada , Feminino , Genótipo , Humanos , Masculino , Pessoa de Meia-Idade , Tetra-Hidrofolatos/genética , Adulto Jovem
4.
Int Clin Psychopharmacol ; 28(5): 238-44, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-23764521

RESUMO

We have recently examined the efficacy of low-dose aripiprazole augmentation for major depressive disorder (MDD), with modest nonsignificant benefit found. In a secondary investigation, we examined whether aripiprazole resulted in improvement in four subscales (depression, anxiety, somatic symptoms, and hostility) of the Kellner Symptom Questionnaire (KSQ). We reanalyzed data from the main outcome study on 221 MDD patients with inadequate response to selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors. Patients were randomized, using the sequential parallel comparison design, into two 30-day phases, as follows: drug/drug (aripiprazole 2 mg/day in phase 1, aripiprazole 5 mg/day in phase 2), placebo/drug (placebo in phase 1, aripiprazole 2 mg/day in phase 2), or placebo/placebo (placebo in both phases). We examined changes in the KSQ score from baseline to endpoint on the basis of the subscaled Well-being and Reversal Distressed Anxiety Subscales. The score for the KSQ depression subscale improved from baseline to the end of follow-up, with a significant advantage for aripiprazole over placebo (P=0.0327). Although improvement was also observed in the anxiety and hostility scales, neither attained a significant advantage over placebo; no significant change was observed for the somatization subscale. Aripiprazole augmentation resulted in a significant improvement compared with placebo augmentation only in the depression subscale of the KSQ; however, the low dose may not have been enough to have an impact on the anxiety and hostility scales. The good tolerability of the low dose may have resulted in the absence of worsening of somatic symptoms. Prospective studies are needed to better characterize the impact of low doses of aripiprazole augmentation on different manifestations of MDD.


Assuntos
Antipsicóticos/uso terapêutico , Transtorno Depressivo Maior/tratamento farmacológico , Piperazinas/uso terapêutico , Quinolonas/uso terapêutico , Adolescente , Adulto , Idoso , Ansiolíticos/administração & dosagem , Ansiolíticos/efeitos adversos , Ansiolíticos/uso terapêutico , Antipsicóticos/administração & dosagem , Antipsicóticos/efeitos adversos , Aripiprazol , Manual Diagnóstico e Estatístico de Transtornos Mentais , Relação Dose-Resposta a Droga , Método Duplo-Cego , Resistência a Medicamentos , Quimioterapia Combinada/efeitos adversos , Feminino , Seguimentos , Hostilidade , Humanos , Masculino , Pessoa de Meia-Idade , Piperazinas/administração & dosagem , Piperazinas/efeitos adversos , Escalas de Graduação Psiquiátrica , Quinolonas/administração & dosagem , Quinolonas/efeitos adversos , Estudos Retrospectivos , Adulto Jovem
5.
Can J Psychiatry ; 57(7): 406-13, 2012 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-22762295

RESUMO

Interest in nonpharmaceutical supplements for treating major depressive disorder (MDD) has increased significantly, both among patients and among clinicians during the past decades. Despite the large array of antidepressants (ADs) available, many patients continue to experience relatively modest response and remission rates, in addition to a burden of side effects that can hinder treatment compliance and acceptability. In this article, we review the literature on folates and S-adenosylmethionine (SAMe), 2 natural compounds linked in the 1-carbon cycle metabolic pathway, for which substantial evidence supports their involvement in mood disorders. Background information, efficacy data, proposed mechanisms of action, and side effects are reviewed. Based on existing data, supplementation with SAMe, as well as with various formulations of folates, appears to be efficacious and well tolerated in reducing depressive symptoms. Compared with other forms of folates, 5-methyltetrahydrofolate (L-methylfolate or 5-MTHF) may represent a preferable treatment option for MDD given its greater bioavailability in patients with a genetic polymorphism, and the lower risk of specific side effects associated with folic acid. Although further randomized controlled trials in this area appear warranted, SAMe and L-methylfolate may represent a useful addition to the AD armamentarium.


Assuntos
Transtorno Depressivo Maior/tratamento farmacológico , Ácidos Pteroilpoliglutâmicos/uso terapêutico , S-Adenosilmetionina/uso terapêutico , Adulto , Antidepressivos/efeitos adversos , Antidepressivos/uso terapêutico , Transtorno Depressivo Maior/fisiopatologia , Transtorno Depressivo Maior/psicologia , Transtorno Depressivo Resistente a Tratamento/tratamento farmacológico , Transtorno Depressivo Resistente a Tratamento/fisiopatologia , Transtorno Depressivo Resistente a Tratamento/psicologia , Método Duplo-Cego , Quimioterapia Combinada , Medicina Baseada em Evidências , Humanos , Transferases de Grupo de Um Carbono/fisiologia , Ácidos Pteroilpoliglutâmicos/efeitos adversos , Ácidos Pteroilpoliglutâmicos/fisiologia , Ensaios Clínicos Controlados Aleatórios como Assunto , S-Adenosilmetionina/efeitos adversos , S-Adenosilmetionina/fisiologia , Tetra-Hidrofolatos/efeitos adversos , Tetra-Hidrofolatos/fisiologia , Tetra-Hidrofolatos/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA